In this study, we found that circPDE5A inhibits the PI3K/AKT signaling pathway by encoding PDE5A-500aa, thereby inhibiting ESCC progression, indicating that circPDE5A may serve as novel a therapeutic target for ESCC treatment. Here, PDE5A is linked to esophageal squamous cell carcinoma.